Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives

Amicus Therapeutics (FOLD) reported mixed Q4 2025 results, with revenue of US$185.2 million and positive basic EPS of US$0.01, but a trailing 12-month net loss of US$27.1 million. While quarterly net income turned positive, the full year still indicates a loss, challenging bullish narratives about profitability and growth. Investors are looking for sustained improvements in net income to solidify the company’s financial standing and justify long-term growth forecasts.